LSL PHARMA GROUP INC., a Canadian based pharmaceutical firm, is pleased to declare the acquisition of Virage Santé, a firm, that specializes in the production and distribution of natural health products (NHPs). LSL Pharma's contract development...
Cipla, a leading global pharmaceutical firm, announced that it will make an additional investment of 3 million euros in Ethris, a company based in Germany that is developing potential treatments for respiratory diseases using its own mRNA...
Aprea Therapeutics, Inc., a biopharmaceutical firm that specializes in precision oncology through synthetic lethality, declared that the first patient has been dosed in the ACESOT-1051 phase 1 study. The study evaluates which is evaluating the...
MGI, an organization focused on building center instruments and advances that drive development in life science, declared partnership with SeqOne, a leading provider of artificial intelligence driven genomic choice support software...
AstraZeneca's Imfinzi (durvalumab) has been approved as a treatment for adult patients with mismatch repair deficient (dMMR) primary, advanced, or recurrent endometrial cancer, in the United States. This can be followed by Imfinzi...
Alembic Pharmaceuticals Ltd announced that the US health agency has granted final approval for its generic Icatibant injectable, which is recommended for the treatment of acute bouts of hereditary angioedema in adults. Alembic Pharmaceuticals...
LED Radiofluidics Corporation, a preclinical biotechnology firm committed to the development of efficient PET radiotracers, and Premium Imaging Inc, a biotechnology company with extensive experience in the clinical transformation and marketing of...
Takeda has signed an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI) that is currently being...
The US Food and Drug Administration (FDA) has approved AstraZeneca's Farxiga (dapagliflozin) for improving glycaemic control in children with type-2 diabetes (T2D) aged 10 and older. The positive outcomes of the paediatric T2NOW phase III trial...
Suven Pharmaceuticals, which is backed by PE company Advent International, said that it has reached a definitive agreement to acquire a controlling stake in Hyderabad-based contract research development organization (CDMO) Sapala Organic for...
, CDSCO.jpg)
